immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer nasdaqimdz facebook google linkedin twitter email rss oct   previous release  next release pdf add to briefcase file is in briefcase immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer seattle and south san francisco calif oct   globe newswire  immune design nasdaqimdz a clinicalstage immunotherapy company focused on cancer today announced the appointment of sergey yurasov md phd as senior vice president of clinical development and chief medical officer sergeys extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development including registration trials and regulatory submissions and reviews make him the optimal leader of our medical team said carlos paya md phd president and chief executive officer at immune design his esteemed career as an immunologist and oncologist spans industry academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current phase  stage products and our nextgeneration approaches in the field of cancer immunotherapy     a boardcertified us licensed hematologistoncologist with more than  years of experience in immunology and oncology dr yurasov joins immune design from clovis oncology where he most recently served as senior vice president clinical development overseeing all clinical activities for its rociletinib rucaparib and lucitanib programs including regulatory approval and launch support for rociletinib and rucaparib  prior to clovis dr yurasov served as associate vicepresident global medicine science at imclone systems a subsidiary of eli lilly  co where he led the development of ramucirumab culminating in the fda submission for second line nonsmall cell lung cancer indication he also served at hoffmanla roche as clinical director of oncology pharma research and early development prior to his industry experience dr yurasov was assistant professor of clinical investigation at rockefeller university where he was the principal investigator for nih funded translational immunology research and clinical instructor in the department of pediatrics at memorial sloankettering cancer center where he was an attending physician dr yurasov received his md from the russian state medical university and his phd in medical sciences from the research institute for pediatric oncology in moscow russia  he thereafter completed his residency in general pediatrics at albert einstein college of medicinejacobi medical center and his subspecialty training in pediatric hematologyoncology at memorial sloankettering cancer center while serving as a research fellow at the rockefeller university in dr m nussenzweigs laboratory immune designs immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies either alone or in combination with other agents said dr yurasov it is rewarding to be involved in such innovative science at the forefront of cancer research i am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates about immune design immune design is a clinicalstage immunotherapy company employing nextgeneration in vivo approaches to enable the bodys immune system to fight disease the companys technologies are engineered to activate the immune systems natural ability to generate andor expand antigenspecific cytotoxic t cells while also enhancing other immune effectors to fight cancer and other chronic diseases  cmb and g the twopronged focus of immune designs ongoing immunooncology clinical programs are the product of its two synergistic discovery platforms zvex® and glaastm immune design has offices in seattle and south san francisco for more information visit wwwimmunedesigncommedia contact julie rathbun rathbun communications julierathbuncommcom  investor contact shari annes annes associates sannesannesassociatescom  immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer globenewswire oct    am edt seattle and south san francisco calif oct   globe newswire  immune design nasdaqimdz a clinicalstage immunotherapy company focused on cancer today announced the appointment of sergey yurasov md phd as senior vice president of clinical development and chief medical officer sergeys extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development including registration trials and regulatory submissions and reviews make him the optimal leader of our medical team said carlos paya md phd president and chief executive officer at immune design his esteemed career as an immunologist and oncologist spans industry academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current phase  stage products and our nextgeneration approaches in the field of cancer immunotherapy     a boardcertified us licensed hematologistoncologist with more than  years of experience in immunology and oncology dr yurasov joins immune design from clovis oncology where he most recently served as senior vice president clinical development overseeing all clinical activities for its rociletinib rucaparib and lucitanib programs including regulatory approval and launch support for rociletinib and rucaparib  prior to clovis dr yurasov served as associate vicepresident global medicine science at imclone systems a subsidiary of eli lilly  co where he led the development of ramucirumab culminating in the fda submission for second line nonsmall cell lung cancer indication he also served at hoffmanla roche as clinical director of oncology pharma research and early development prior to his industry experience dr yurasov was assistant professor of clinical investigation at rockefeller university where he was the principal investigator for nih funded translational immunology research and clinical instructor in the department of pediatrics at memorial sloankettering cancer center where he was an attending physician dr yurasov received his md from the russian state medical university and his phd in medical sciences from the research institute for pediatric oncology in moscow russia  he thereafter completed his residency in general pediatrics at albert einstein college of medicinejacobi medical center and his subspecialty training in pediatric hematologyoncology at memorial sloankettering cancer center while serving as a research fellow at the rockefeller university in dr m nussenzweigs laboratory if you liked this article you might like  stocks insiders love right now insiders at these companies have been scooping up shares of their own stocks lately roberto pedone sep    pm edt  stocks spiking on big volume heres a technical look at how to trade seven stocks that are rising on unusual volume recently roberto pedone jun    am edt  stocks making big moves on unusual volume these stocks rising on unusual volume are within range of triggering breakout trades roberto pedone mar    am edt  stocks insiders love right now insiders at these companies have been scooping up shares o their own stock lately roberto pedone apr    am edt advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer globenewswire oct    am edt immune designs immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies either alone or in combination with other agents said dr yurasov it is rewarding to be involved in such innovative science at the forefront of cancer research i am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates about immune design immune design is a clinicalstage immunotherapy company employing nextgeneration in vivo approaches to enable the bodys immune system to fight disease the companys technologies are engineered to activate the immune systems natural ability to generate andor expand antigenspecific cytotoxic t cells while also enhancing other immune effectors to fight cancer and other chronic diseases  cmb and g the twopronged focus of immune designs ongoing immunooncology clinical programs are the product of its two synergistic discovery platforms zvex ® and glaas tm immune design has offices in seattle and south san francisco for more information visit wwwimmunedesigncom media contactjulie rathbunrathbun communicationsjulierathbuncommcom investor contactshari annesannes associatessannesannesassociatescom if you liked this article you might like  stocks insiders love right now insiders at these companies have been scooping up shares of their own stocks lately roberto pedone sep    pm edt  stocks spiking on big volume heres a technical look at how to trade seven stocks that are rising on unusual volume recently roberto pedone jun    am edt  stocks making big moves on unusual volume these stocks rising on unusual volume are within range of triggering breakout trades roberto pedone mar    am edt  stocks insiders love right now insiders at these companies have been scooping up shares o their own stock lately roberto pedone apr    am edt advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft yurasov sergey  immune design insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsyurasov sergeyimmune design imdzsr vp clinic devel  cmo not rankedyurasov sergeys performanceyurasov sergey has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked yurasov sergeys trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction dateimdzimmune designsr vp clinic devel  cmouninformative buyjan  yurasov sergey has not reported any informative transactions for imdz therefore performance cannot be measured track record datetransactionamountno of sharesprice per shareprofitform  jan   uninformative buy    na see all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by immune design corporation appoints sergey yurasov m d ph d as senior vice president of clinical development and chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       immune design corporation imdz appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs seattle and south san francisco calif oct   globe newswire  immune design nasdaqimdz a clinicalstage immunotherapy company focused on cancer today announced the appointment of sergey yurasov md phd as senior vice president of clinical development and chief medical officer “sergey’s extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development including registration trials and regulatory submissions and reviews make him the optimal leader of our medical team” said carlos paya md phd president and chief executive officer at immune design “his esteemed career as an immunologist and oncologist spans industry academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current phase  stage products and our nextgeneration approaches in the field of cancer immunotherapy” a boardcertified us licensed hematologistoncologist with more than  years of experience in immunology and oncology dr yurasov joins immune design from clovis oncology where he most recently served as senior vice president clinical development overseeing all clinical activities for its rociletinib rucaparib and lucitanib programs including regulatory approval and launch support for rociletinib and rucaparib prior to clovis dr yurasov served as associate vicepresident global medicine science at imclone systems a subsidiary of eli lilly  co where he led the development of ramucirumab culminating in the fda submission for second line nonsmall cell lung cancer indication he also served at hoffmanla roche as clinical director of oncology pharma research and early development prior to his industry experience dr yurasov was assistant professor of clinical investigation at rockefeller university where he was the principal investigator for nih funded translational immunology research and clinical instructor in the department of pediatrics at memorial sloankettering cancer center where he was an attending physician dr yurasov received his md from the russian state medical university and his phd in medical sciences from the research institute for pediatric oncology in moscow russia he thereafter completed his residency in general pediatrics at albert einstein college of medicinejacobi medical center and his subspecialty training in pediatric hematologyoncology at memorial sloankettering cancer center while serving as a research fellow at the rockefeller university in dr m nussenzweig’s laboratory immune design’s immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies either alone or in combination with other agents said dr yurasov it is rewarding to be involved in such innovative science at the forefront of cancer research i am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates about immune design immune design is a clinicalstage immunotherapy company employing nextgeneration in vivo approaches to enable the bodys immune system to fight disease the companys technologies are engineered to activate the immune systems natural ability to generate andor expand antigenspecific cytotoxic t cells while also enhancing other immune effectors to fight cancer and other chronic diseases cmb and g the twopronged focus of immune designs ongoing immunooncology clinical programs are the product of its two synergistic discovery platforms zvex® and glaastm immune design has offices in seattle and south san francisco for more information visit wwwimmunedesigncom media contact julie rathbun rathbun communications julierathbuncommcom  investor contact shari annes annes associates sannesannesassociatescom  read at biospacecom related news immune design corporation imdz announces advancement of first glaasbased allergy program into clinical development how trump was named grand benefactor for a danafarber cancer institute gala without donating a penny immune design corporation imdz prices public offering of common stock how mylan myl ceos mom helped boost epipen sales immune design corporation imdz announces proposed public offering of common stock boston therapeutics completes private offering appoints new ceo immune design corporation imdz reports second quarter  financial results and provides corporate update the scientific advisors at theranos wont or cant talk asco immune design corporation imdz releases new pfs os and tme data from trials of three immunooncology product candidates mylan myl ceo draws fire over use of private jet please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • immune design corporation   • biotechpharma  personnel                 immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer  pharmavoice  pharmavoice read think participate subscribe  register  log in xsite login username password lost your password dont have an accountclick here to register for freebenefits of registered usersregistered user can access and download all contenthave a questionemail customer servicecall proceed as guest download as guest guests must provide the below information each time you download content from pharmavoicecomcontent will be sent to your inbox email  first name  last name  title  company  dont have an accountclick here to registerbenefits of registered users registered user can access and download all content without inputting information multiple times for multiple downloadsget your free subscription to pharmavoice magazineclick one of the links below to pick what type of subscription youd like its completely free pharmavoice print and digital subscription pharmavoice digital subscription only pharmavoice print subscription onlyalready subscribedclick here to loginhave a questionemail customer servicecall forgot your passwordfill out the form below and we will email you a new one all you have to do is check your mail and you will be directed back to pharmavoicecom email or username remember your passwordclick here to loginhave a questioncontact customer servicenewsblogrdcommercialoperationscurrent issuemagazinecurrent issuedigital editionarchiveseditorialadvertisecirculationreprintslist rentalssubscribepharmavoice pharmavoice  celebrationnominatesubmission guidelinescurrent red jacket awardcontact editorresourcesarticlescase studiesebookspodcastswebinarswhite papersvideoseventspharmavoice  celebrationindustry eventswebinarseditorialeditorial calendareditorial scopephotography guidelinespharmavoice innovation issuecontact editoradvertiseprint advertisingonline advertisingemail advertisingmarketing solutionsterms and conditionscontact publishersubscribemagazine subscriptionpharmavoice  celebrationhomeview digital editionmagazinenewsblogcase studiesebookspodcastswebinarswhite papersvideosadvertisesubscribe all news releases upload news releasenews release immune design appoints sergey yurasov md phd as senior vice president of clinical development and chief medical officer sourceglobe newswire october  seattle and south san francisco calif oct   globe newswire — immune design nasdaqimdz a clinicalstage immunotherapy company focused on cancer today announced the appointment of sergey yurasov md phd as senior vice president of clinical development and chief medical officer“sergey’s extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development including registration trials and regulatory submissions and reviews make him the optimal leader of our medical team” said carlos paya md phd president and chief executive officer at immune design “his esteemed career as an immunologist and oncologist spans industry academia and clinical practice and will bring invaluable expertise and insight to guide the further advancement of our current phase  stage products and our nextgeneration approaches in the field of cancer immunotherapy”a boardcertified us licensed hematologistoncologist with more than  years of experience in immunology and oncology dr yurasov joins immune design from clovis oncology where he most recently served as senior vice president clinical development overseeing all clinical activities for its rociletinib rucaparib and lucitanib programs including regulatory approval and launch support for rociletinib and rucaparib prior to clovis dr yurasov served as associate vicepresident global medicine science at imclone systems a subsidiary of eli lilly  co where he led the development of ramucirumab culminating in the fda submission for second line nonsmall cell lung cancer indication he also served at hoffmanla roche as clinical director of oncology pharma research and early development prior to his industry experience dr yurasov was assistant professor of clinical investigation at rockefeller university where he was the principal investigator for nih funded translational immunology research and clinical instructor in the department of pediatrics at memorial sloankettering cancer center where he was an attending physiciandr yurasov received his md from the russian state medical university and his phd in medical sciences from the research institute for pediatric oncology in moscow russia he thereafter completed his residency in general pediatrics at albert einstein college of medicinejacobi medical center and his subspecialty training in pediatric hematologyoncology at memorial sloankettering cancer center while serving as a research fellow at the rockefeller university in dr m nussenzweig’s laboratory“immune design’s immunotherapy approaches offer a promising approach to address the shortcomings of existing therapies either alone or in combination with other agents” said dr yurasov “it is rewarding to be involved in such innovative science at the forefront of cancer research i am pleased to join this distinguished team and look forward to help guide the development of these innovative product candidates”about immune designimmune design is a clinicalstage immunotherapy company employing nextgeneration in vivo approaches to enable the body’s immune system to fight disease the company’s technologies are engineered to activate the immune system’s natural ability to generate andor expand antigenspecific cytotoxic t cells while also enhancing other immune effectors to fight cancer and other chronic diseases cmb and g the twopronged focus of immune design’s ongoing immunooncology clinical programs are the product of its two synergistic discovery platforms zvex® and glaastm immune design has offices in seattle and south san francisco for more information visit wwwimmunedesigncom feature this posted in human resources operationspost a comment click here to cancel replyyou must be logged in to post a comment featurednews releases agile therapeutics reports second quarter  financial results sourceglobe newswire july   view agios to webcast conference call of second quarter  financial results on august   sourceglobe newswire july   view penicillin market  company profile industry trends share size and  forecasts says a new research report at reportsnreports sourceprnewswire july   view cesca therapeutics announces issuance of new cellular processing patent poised to revolutionize cart cell manufacturing sourceglobe newswire july   view us court of appeals for the federal circuit affirms merus’ inequitable conduct claim against regeneron sourceglobe newswire july   view current issue june  digital edition extra copies reprints subscriptions subscribe for free accessget free access to pharmavoice magazine webinars white papers podcasts videos article downloads tips and event discounts delivered to your inbox coveragecurrent issuenewsblogresourcescase studiesebookspodcastswebinarswhite papersvideosuser centersubscribeadvertiseabout uscontact ussubscribeconnect with usnewsletterstwitterlinked infacebookgooglehomeadvertiseblogcontact  pharmavoice all rights reserved feedback sergey yurasov  profile  scrum alliance get certified  transform your world of work today menu sign in menu community certificant directory expert perspectives spotlight member articles news sponsorship application about us faqs home » community sergey yurasov    delivery director first line software location nizhny novgorod certifications certified scrummaster credentials links httpfirstlinesoftwarecom biography linkedin profile first line software find a course » certified scrummaster certified scrum product owner certified scrum developer certified agile leadership continuing education » virtual learning » find education providers » certified scrum trainer certified enterprise coach registered education provider   newsletter signup subscribe